Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| GERN | GERON CORP | 2026-05-22 14:59:41 | 1.28 | 0.02 | 1.58 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GERN | 0000886744 | GERON CORP | US3741631036 | 549300T282D7Z2YESL90 | 752287752 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 919 EAST HILLSDALE BOULEVARD | FOSTER CITY | CA | 94404 | UNITED STATES | US | 6504737700 | 919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA, 94404 | 919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA, 94404 | GERON CORPORATION | Biotechnology | 1990 | John Scarlett | 82 | http://www.geron.com/ | 860,500,000 | 639,856,222 | 641,520,974 | Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase. | 2026-05-21 17:26:00 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 860,500,000 | -1,570,200,000 | -64.5987 | 640,544,661 | 3,640,191 | 0.5715 |
| 2024 | 2,430,700,000 | 1,036,154,000 | 74.3005 | 636,904,470 | 90,845,161 | 16.6365 |
| 2023 | 1,394,546,000 | 891,359,000 | 177.1427 | 546,059,309 | 37,336,823 | 7.3393 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Ahmed Elnawawi | Executive Vice President, Chief Commercial Officer | 2025 | 107,692 | 200,000 | 0 | 0 | 242 | 2,881,334 |
| Harout Semerjian | Chief Executive Officer, President | 2025 | 321,538 | 0 | 0 | 203,000 | 1,817 | 10,221,755 |
| John A. Scarlett, M.D. | President, Chief Executive Officer, Chairman Of The Board | 2025 | 309,781 | 0 | 1,078,300 | 0 | 1,726,569 | 7,422,754 |
| Michelle J. Robertson | Secretary, Executive Vice President, Treasurer, Chief Financial Officer | 2025 | 559,800 | 0 | 289,300 | 239,300 | 11,452 | 2,250,082 |
| Joseph Eid | Executive Vice President, Chief Medical Officer | 2025 | 650,000 | 0 | 0 | 339,600 | 11,452 | 1,001,052 |
| Fiscal Year | Employee Count |
|---|---|
| 2016 | 15 |
| 2015 | 17 |
| 2014 | 42 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 183,623,000 | 76,495,000 | 237,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | 183,881,000 | 76,994,000 | 237,000 |
| Research And Development Expenses | 71,433,000 | 103,738,000 | 125,046,000 |
| General And Administrative Expenses | 159,256,000 | 145,732,000 | 69,135,000 |
| Operating Expenses | 252,466,000 | 250,726,000 | 194,181,000 |
| Operating Income | -68,585,000 | -173,732,000 | -193,944,000 |
| Net Income | -83,500,000 | -174,572,000 | -184,127,000 |
| Earnings Per Share Basic | -0.13 | -0.27 | -0.32 |
| Earnings Per Share Diluted | -0.13 | -0.27 | -0.32 |
| Weighted Average Shares Outstanding Basic | 666,662,989 | 646,033,247 | 570,645,405 |
| Weighted Average Shares Outstanding Diluted | 666,662,989 | 646,033,247 | 570,645,405 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 77,560,000 | 79,016,000 | 70,023,000 |
| Marketable Securities Current | — | 327,550,000 | 263,676,000 |
| Accounts Receivable | 36,987,000 | 35,946,000 | — |
| Inventories | 116,636,000 | 38,714,000 | — |
| Non Trade Receivables | 2,239,000 | 2,853,000 | 1,655,000 |
| Other Assets Current | 4,610,000 | 5,053,000 | 4,879,000 |
| Total Assets Current | 520,271,000 | 490,992,000 | 341,348,000 |
| Marketable Securities Non Current | — | 94,519,000 | 43,298,000 |
| Property Plant And Equipment | 884,000 | 1,310,000 | 1,177,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 50,269,000 | 102,789,000 | 52,728,000 |
| Total Assets | 570,540,000 | 593,781,000 | 394,076,000 |
| Accounts Payable | 11,257,000 | 8,595,000 | 6,161,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 3,110,000 | 2,186,000 | 46,893,000 |
| Other Liabilities Current | 51,340,000 | 35,549,000 | 40,308,000 |
| Total Liabilities Current | 111,542,000 | 88,298,000 | 108,070,000 |
| Long Term Debt | 119,547,000 | 118,476,000 | 35,051,000 |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 233,126,000 | 225,163,000 | 38,057,000 |
| Total Liabilities | 344,668,000 | 313,461,000 | 146,127,000 |
| Common Stock | 640,000 | 606,000 | 545,000 |
| Retained Earnings | -1,855,841,000 | -1,772,341,000 | -1,597,769,000 |
| Accumulated Other Comprehensive Income | 269,000 | 261,000 | 185,000 |
| Total Shareholders Equity | 225,872,000 | 280,320,000 | 247,949,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 474,000 | 546,000 | 442,000 |
| Share Based Compensation Expense | 26,659,000 | 31,185,000 | 18,526,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 991,000 | 35,695,000 | — |
| Change In Inventories | 77,922,000 | 37,971,000 | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 2,661,000 | 2,435,000 | -4,029,000 |
| Change In Other Liabilities | 7,689,000 | 9,049,000 | 2,224,000 |
| Cash From Operating Activities | -111,037,000 | -218,618,000 | -167,743,000 |
| Purchases Of Marketable Securities | 304,421,000 | 476,932,000 | 475,594,000 |
| Sales Of Marketable Securities | 411,717,000 | 371,608,000 | 296,102,000 |
| Acquisition Of Property Plant And Equipment | — | 680,000 | 830,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 107,247,000 | -106,004,000 | -180,322,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 1,520,000 | 32,683,000 | 13,070,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | 0 | 121,120,000 | 29,700,000 |
| Repayment Of Long Term Debt | 0 | 86,554,000 | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 2,267,000 | 334,372,000 | 362,021,000 |
| Change In Cash | -1,436,000 | 9,738,000 | 13,929,000 |
| Cash At End Of Period | 77,560,000 | 79,016,000 | 70,023,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 11,712,000 | 10,364,000 | -7,017,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -0.13 | -0.27 | -0.32 |
| Price To Earnings Ratio | -10.1538 | -13.1111 | -6.5938 |
| Earnings Growth Rate | -51.8519 | -15.625 | -13.5135 |
| Price Earnings To Growth Ratio | 0.1958 | 0.8391 | 0.4879 |
| Book Value Per Share | 0.3388 | 0.4339 | 0.4345 |
| Price To Book Ratio | 3.896 | 8.1584 | 4.8561 |
| Ebitda | -50,369,000 | -155,522,000 | -175,373,000 |
| Enterprise Value | 925,092,145.48 | 2,328,603,694.38 | 1,215,982,804.55 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.543 | 0.4304 | 0.3305 |
| Capital Expenditures | 48,000 | 679,000 | 826,000 |
| Free Cash Flow | -111,085,000 | -219,297,000 | -168,569,000 |
| Return On Equity | -0.3697 | -0.6228 | -0.7426 |
| One Year Beta | 1.1381 | 0.6129 | 1.4491 |
| Three Year Beta | 1.093 | 1.2051 | 1.2135 |
| Five Year Beta | 1.1267 | 0.9171 | 0.9765 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Williams Timothy | EVP and Chief Legal Officer | 2026-04-13 | 2,500,000 | A | 2,500,000 |
| Spiegel Robert J. | Director | 2026-03-31 | 5,243 | A | 199,707 |
| Andrews Patricia S | Director | 2026-03-25 | 270,000 | A | 270,000 |
| Chinoporos Constantine | Director | 2026-03-25 | 270,000 | A | 270,000 |
| ROBERTSON MICHELLE | EVP, CHIEF FINANCIAL OFFICER | 2026-02-18 | 27,500 | A | 27,500 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| SEGALL BRYANT & HAMILL, LLC | 2026-03-31 | 7,062,672 | 4,740,048 | 1.49 |
| Vivo Capital, LLC | 2026-03-31 | 12,920,978 | 8,671,797 | 1.49 |
| JANUS HENDERSON GROUP PLC | 2026-03-31 | 3,303,915 | 2,218,196 | 1.4895 |
| Alternative Investment Advisors, LLC. | 2026-03-31 | 58,524 | 39,278 | 1.49 |
| J. Goldman & Co LP | 2026-03-31 | 909,882 | 610,659 | 1.49 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Bridge Builder Trust | 2026-03-31 | Bridge Builder Small/Mid Cap Growth Fund | BBGSX | 103,639 | 154,422.11 | 0.0017 |
| ALPS ETF Trust | 2026-02-28 | ALPS Medical Breakthroughs ETF | SBIO | 568,951 | 955,837.68 | 0.6925 |
| VALIC Co I | 2026-02-28 | Small Cap Index Fund | VCSLX | 224,012 | 376,340.16 | 0.0304 |
| Invesco Exchange-Traded Fund Trust II | 2026-02-28 | Invesco Nasdaq Biotechnology ETF | IBBQ | 35,647 | 59,886.96 | 0.0791 |
| Invesco Exchange-Traded Fund Trust II | 2026-02-28 | Invesco NASDAQ Future Gen 200 ETF | QQQS | 56,097 | 94,242.96 | 0.6697 |